miltefosine has been researched along with Hematologic Diseases in 1 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 6.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 2.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sindermann, H | 1 |
| Engel, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for miltefosine and Hematologic Diseases
| Article | Year |
|---|---|
Development of miltefosine as an oral treatment for leishmaniasis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Age | 2006 |